Two years ago, Amgen’s David Beier estimated that the biotechnology industry had lost $100 billion in its three decades, but still enjoyed a stock market valuation of $500 billion. By the end of 2006, experience seemed to elbow aside hope. That year, investors yanked $6.4 billion from funds focused on biotechnology and healthcare in the US, the industry’s capital. They withdrew another $5.4...
Sanjay Sinha, chief investment officer at SBI Mutual Fund, has been one of the most out-standing fund managers in India. An alumnus of IIM Calcutta, he joined the fund in November 2005 after a long stint with UTI where he began his career selling mutual funds. He has seen various market cycles and observed the changing face of the Indian investor over the past two decades. In an interview with...
9 fund houses have bought these 11 stocks when the market was going down. Should you also buy them? Debashis Basu & Shailendra Lotlikar offer some clues
When fund managers buy a stock, it is supposed to be moving into ‘strong’ hands because they are supposed to be buying with the long term in view and have the resources to do a lot of in-depth research before they place their buy orders....
